Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$54.88 - $79.29 $823,200 - $1.19 Million
-15,000 Reduced 60.0%
10,000 $568,000
Q2 2020

Aug 14, 2020

SELL
$25.95 - $43.15 $1.18 Million - $1.95 Million
-45,300 Reduced 64.44%
25,000 $1.04 Million
Q1 2019

May 15, 2019

SELL
$89.33 - $163.65 $2.68 Million - $4.91 Million
-30,000 Reduced 29.91%
70,300 $11.2 Million
Q4 2018

Feb 14, 2019

BUY
$81.94 - $139.71 $409,700 - $698,550
5,000 Added 5.25%
100,300 $9.61 Million
Q2 2018

Aug 14, 2018

BUY
$140.36 - $175.76 $7.06 Million - $8.84 Million
50,300 Added 111.78%
95,300 $14.9 Million
Q1 2018

May 15, 2018

BUY
$152.15 - $192.33 $2.28 Million - $2.88 Million
15,000 Added 50.0%
45,000 $7.25 Million
Q3 2017

Nov 14, 2017

BUY
$61.4 - $88.52 $1.84 Million - $2.66 Million
30,000
30,000 $1.87 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.